# Todd A Alonzo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5636869/publications.pdf

Version: 2024-02-01

| 194 | 4,939 | 147801 | 102487 |
|---|---|---|---|
| papers | citations | 31 h-index | 66 g-index |

| 197 | 197 | 197 | 5741 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia. JAMA Oncology, 2022, 8, 79. | 7.1 | 36 |
| 2 | CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2022, 40, 252-261. | 1.6 | 18 |
| 3 | Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. Cancers, 2022, 14, 616. | 3.7 | 4 |
| 4 | Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance?. Pediatric Blood and Cancer, 2022, , e29613. | 1.5 | 1 |
| 5 | Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Instituteâ€“Children's Oncology Group Pediatric MATCH Trial. Journal of Clinical Oncology, 2022, 40, 2224-2234. | 1.6 | 45 |
| 6 | Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. Journal of Clinical Oncology, 2022, 40, 2235-2245. | 1.6 | 21 |
| 7 | The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. Haematologica, 2021, 106, 630-634. | 3.5 | 29 |
| 8 | Results of a phase 2, multicenter, singleâ€arm, openâ€label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. Pediatric Blood and Cancer, 2021, 68, e28946. | 1.5 | 3 |
| 9 | Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. Cancers, 2021, 13, 2336. | 3.7 | 30 |
| 10 | CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Childrenâ€™s Oncology Group. Blood, 2021, 138, 1137-1147. | 1.4 | 55 |
| 11 | High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood, 2021, 138, 2337-2346. | 1.4 | 16 |
| 12 | Cancer Informatics for Cancer Centers: Scientific Drivers for Informatics, Data Science, and Care in Pediatric, Adolescent, and Young Adult Cancer. JCO Clinical Cancer Informatics, 2021, 5, 881-896. | 2.1 | 3 |
| 13 | Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NFâ€ºB subunit RelA. Proteomics - Clinical Applications, 2021, , 2100072. | 1.6 | 4 |
| 14 | KMT2A Partial Tandem Duplications (KMT2A-PTD) Is a Rare, but Recurrent Genomic Event in Childhood AML and Associated with High Rate of Co-Occurring FLT3 Mutations. Blood, 2021, 138, 609-609. | 1.4 | 0 |
| 15 | ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications. Blood, 2021, 138, 2356-2356. | 1.4 | 4 |
| 16 | Significant Improvements in Survival for Patients with t(6;9)(p23;q34)/DEK-NUP214 in Contemporary Trials with Intensification of Therapy: A Report from the Children's Oncology Group. Blood, 2021, 138, 519-519. | 1.4 | 3 |
| 17 | Epigenetic Silencing of CD34 in AML and Association with Outcome in KMT2A Fusions. Blood, 2021, 138, 802-802. | 1.4 | 0 |
| 18 | Gene Expression Analysis of CML Patients across the Age Spectrum. Blood, 2021, 138, 1473-1473. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | EZH2-Mediated MHC Class II Silencing Drives Immune Evasion in AML with t(16;21) (FUS-ERG). Blood, 2021, 138, 374-374. | 1.4 | 0 |
| 20 | Integrated Genomic Analysis Identifies UBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia. Blood, 2021, 138, LBA-4-LBA-4. | 1.4 | 0 |
| 21 | Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers, 2021, 13, 6263. | 3.7 | 7 |
| 22 | Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431. Archives of Pathology and Laboratory Medicine, 2020, 144, 466-472. | 2.5 | 9 |
| 23 | Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Cytometry Part B - Clinical Cytometry, 2020, 98, 52-56. | 1.5 | 17 |
| 24 | Mixedâ€phenotype acute leukemia: A cohort and consensus research strategy from the Childrenâ€™s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer, 2020, 126, 593-601. | 4.1 | 32 |
| 25 | A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study. Biology of Blood and Marrow Transplantation, 2020, 26, 712-717. | 2.0 | 8 |
| 26 | Adaptive trial designs in diagnostic accuracy research. Statistics in Medicine, 2020, 39, 591-601. | 1.6 | 11 |
| 27 | Morphologic remission status is limited compared to Î”N flow cytometry: a Childrenâ€™s Oncology Group AAML0531 report. Blood Advances, 2020, 4, 5050-5061. | 5.2 | 21 |
| 28 | Outcomes for Step-Wise Implementation of a Human Papillomavirus Testingâ€“Based Cervical Screen-and-Treat Program in El Salvador. JCO Global Oncology, 2020, 6, 1519-1530. | 1.8 | 12 |
| 29 | Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Childrenâ€™s Oncology Group. Blood Advances, 2020, 4, 6000-6008. | 5.2 | 11 |
| 30 | Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2020, 38, 2170-2177. | 1.6 | 35 |
| 31 | Information fraction estimation based on the number of events within the standard treatment regimen. Biometrical Journal, 2020, 62, 1960-1972. | 1.0 | 4 |
| 32 | Comprehensive Transcriptome Profiling of Cryptic CBFA2T3â€“GLIS2 Fusionâ€“Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. Clinical Cancer Research, 2020, 26, 726-737. | 7.0 | 42 |
| 33 | Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia. Blood, 2020, 136, 38-39. | 1.4 | 3 |
| 34 | Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol. Blood, 2020, 136, 39-39. | 1.4 | 1 |
| 35 | Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Blood, 2020, 136, 39-40. | 1.4 | 1 |
| 36 | Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia. Blood, 2020, 136, 28-29. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts. Blood, 2020, 136, 20-21. | 1.4 | 1 |
| 38 | Comparisons of New HIV Rapid Test Kit Performance. AIDS and Behavior, 2019, 23, 313-317. | 2.7 | 4 |
| 39 | ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Childrenâ€™s Oncology Group AAML0531 Trial. Blood Cancer Journal, 2019, 9, 51. | 6.2 | 26 |
| 40 | Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials. Pediatric Blood and Cancer, 2019, 66, e27700. | 1.5 | 6 |
| 41 | Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Childrenâ€™s Oncology Group Study AAML0631. Journal of Pediatric Hematology/Oncology, 2019, 41, 51-55. | 0.6 | 20 |
| 42 | Evaluating the predictive value of measures of susceptibility to tobacco and alternative tobacco products. Addictive Behaviors, 2019, 96, 50-55. | 3.0 | 16 |
| 43 | Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML. Blood, 2019, 134, 3772-3772. | 1.4 | 7 |
| 44 | Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood, 2019, 134, 459-459. | 1.4 | 6 |
| 45 | Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study. Blood, 2019, 134, 461-461. | 1.4 | 12 |
| 46 | High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction. Blood, 2019, 134, 118-118. | 1.4 | 3 |
| 47 | Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile. Blood, 2019, 134, 119-119. | 1.4 | 6 |
| 48 | Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031. Blood, 2019, 134, 292-292. | 1.4 | 19 |
| 49 | Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood, 2019, 134, 703-703. | 1.4 | 1 |
| 50 | Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial. Blood, 2019, 134, 2676-2676. | 1.4 | 0 |
| 51 | Estimation of the volume under the receiver-operating characteristic surface adjusting for non-ignorable verification bias. Statistical Methods in Medical Research, 2018, 27, 715-739. | 1.5 | 4 |
| 52 | The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nature Medicine, 2018, 24, 103-112. | 30.7 | 525 |
| 53 | Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. Blood, 2018, 132, 1584-1592. | 1.4 | 45 |
| 54 | Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research, 2017, 23, 3649-3656. | 7.0 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Childrenâ€™s Oncology Group report. Blood, 2017, 129, 3051-3058. | 1.4 | 19 |
| 56 | Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2017, 64, e26612. | 1.5 | 33 |
| 57 | Improved outcomes for myeloid leukemia of Down syndrome: a report from the Childrenâ€™s Oncology Group AAML0431 trial. Blood, 2017, 129, 3304-3313. | 1.4 | 71 |
| 58 | Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Childrenâ€™s Oncology Group protocol AAML0531. Haematologica, 2017, 102, 2058-2068. | 3.5 | 22 |
| 59 | Gemtuzumab ozogamicin in infants with AML: results from the Childrenâ€™s Oncology Group trials AAML03P1 and AAML0531. Blood, 2017, 130, 943-945. | 1.4 | 16 |
| 60 | Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Childrenâ€™s Oncology Group. Haematologica, 2017, 102, e340-e343. | 3.5 | 4 |
| 61 | Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. British Journal of Haematology, 2017, 176, 86-91. | 2.5 | 29 |
| 62 | Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. Journal of Clinical Oncology, 2017, 35, 3021-3029. | 1.6 | 62 |
| 63 | CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Childrenâ€™s Oncology Group Trial AAML0531. Journal of Clinical Oncology, 2017, 35, 2674-2682. | 1.6 | 120 |
| 64 | Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Childrenâ€™s Oncology Group report. Oncotarget, 2017, 8, 90037-90049. | 1.8 | 5 |
| 65 | Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group. Blood, 2017, 130, 883-883. | 1.4 | 2 |
| 66 | Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group. Frontiers in Genetics, 2016, 7, 139. | 2.3 | 2 |
| 67 | Adapting CryoPen, a Non-Gas Based Cryotherapy System for Use in Low- and Middle-Income Countries. Journal of Global Oncology, 2016, 2, 11s-12s. | 0.5 | 1 |
| 68 | Inverse probability weighting estimation of the volume under the ROC surface in the presence of verification bias. Biometrical Journal, 2016, 58, 1338-1356. | 1.0 | 5 |
| 69 | Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group. International Journal of Cancer, 2016, 139, 1930-1935. | 5.1 | 7 |
| 70 | Early discharge as a mediator of greater <scp>ICU</scp>â€level care requirements in patients not enrolled on the <scp>AAML</scp>0531 clinical trial: a Children's Oncology Group report. Cancer Medicine, 2016, 5, 2412-2416. | 2.8 | 4 |
| 71 | Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. Blood, 2016, 127, 3424-3430. | 1.4 | 79 |
| 72 | CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. Blood, 2016, 127, 3094-3098. | 1.4 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. Journal of Hematology and Oncology, 2016, 9, 82. | 17.0 | 22 |
| 74 | miRâ€155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 2096-2103. | 1.5 | 21 |
| 75 | Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2016, 34, 3766-3772. | 1.6 | 17 |
| 76 | CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Childrenâ€™s Oncology Group Trial AAML0531. Journal of Clinical Oncology, 2016, 34, 747-755. | 1.6 | 116 |
| 77 | Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research, 2016, 22, 1951-1957. | 7.0 | 49 |
| 78 | Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Research, 2016, 76, 2197-2205. | 0.9 | 133 |
| 79 | A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Childrenâ€™s Oncology Group. Leukemia and Lymphoma, 2016, 57, 1567-1574. | 1.3 | 13 |
| 80 | Prognostic Significance of 11q23/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531. Blood, 2016, 128, 1211-1211. | 1.4 | 14 |
| 81 | Excess Treatment-Related Mortality in Obese Children and Adolescents with Acute Myeloid Leukemia on AAML0531: A Report from the Children's Oncology Group. Blood, 2016, 128, 2790-2790. | 1.4 | 1 |
| 82 | Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative. Blood, 2016, 128, 2873-2873. | 1.4 | 5 |
| 83 | FLT3 Mutations in Pediatric Acute Promyelocytic Leukemia; A Report from the Children's Oncology Group AAML0631 Trial. Blood, 2016, 128, 2884-2884. | 1.4 | 2 |
| 84 | The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group. Blood, 2016, 128, 899-899. | 1.4 | 10 |
| 85 | Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood, 2016, 128, 2846-2846. | 1.4 | 2 |
| 86 | CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study. Blood, 2016, 128, 2743-2743. | 1.4 | 0 |
| 87 | Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group. Blood, 2016, 128, 2794-2794. | 1.4 | 0 |
| 88 | The Effect of Traumatic Diagnostic Lumbar Puncture in De Novo Pediatric Acute Myeloid Leukemia - a Report from the Children's Oncology Group. Blood, 2016, 128, 4016-4016. | 1.4 | 0 |
| 89 | Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration. Blood, 2016, 128, 1687-1687. | 1.4 | 1 |
| 90 | A microRNA Expression-Based Model Predicts Event Free Survival in Pediatric Acute Myeloid Leukemia. Blood, 2016, 128, 1210-1210. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Comparison of administrative/billing data to expected protocolâ€mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1184-1189. | 1.5 | 12 |
| 92 | Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 629-636. | 1.5 | 43 |
| 93 | Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood, 2015, 125, 516-524. | 1.4 | 69 |
| 94 | Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica, 2015, 100, e496-e500. | 3.5 | 3 |
| 95 | Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group. Cancer Genetics, 2015, 208, 408-413. | 0.4 | 3 |
| 96 | Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research, 2015, 21, 3187-3195. | 7.0 | 18 |
| 97 | The genomic landscape of juvenile myelomonocytic leukemia. Nature Genetics, 2015, 47, 1326-1333. | 21.4 | 233 |
| 98 | Comparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus. Open Forum Infectious Diseases, 2015, 2, ofv101. | 0.9 | 23 |
| 99 | Rearrangements in Nucleoporin Family of Genes in Childhood Acute Myeloid Leukemia: A Report from Children Oncology Group and NCI/COG Target AML Initiative. Blood, 2015, 126, 169-169. | 1.4 | 2 |
| 100 | Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631. Blood, 2015, 126, 219-219. | 1.4 | 3 |
| 101 | ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative. Blood, 2015, 126, 2587-2587. | 1.4 | 1 |
| 102 | Prognostic Relevance of Recurrent Genetic Aberrations in Pediatric Acute Megakaryoblastic Leukemia. Blood, 2015, 126, 2598-2598. | 1.4 | 1 |
| 103 | Heirarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531. Blood, 2015, 126, 561-561. | 1.4 | 3 |
| 104 | Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative. Blood, 2015, 126, 687-687. | 1.4 | 2 |
| 105 | Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative. Blood, 2015, 126, 87-87. | 1.4 | 19 |
| 106 | Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children's Oncology Group. PLoS ONE, 2015, 10, e0125290. | 2.5 | 10 |
| 107 | Merging Childrenâ€™s Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Childrenâ€™s Oncology Group. PLoS ONE, 2015, 10, e0143480. | 2.5 | 16 |
| 108 | TET2 Mutations Are Highly Associated with RUNX1-RUNX1T1 Translocations and NPMc+ in Childhood AML: a Report from Children's Oncology Group AAML03P1, AAML0531 and NCI/COG Target AML Initiative. Blood, 2015, 126, 1368-1368. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study. Blood, 2015, 126, 1260-1260. | 1.4 | 0 |
| 110 | Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106. Blood, 2015, 126, 2576-2576. | 1.4 | 0 |
| 111 | Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia. Blood, 2015, 126, 88-88. | 1.4 | 0 |
| 112 | Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative. Blood, 2015, 126, 170-170. | 1.4 | 0 |
| 113 | Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. Journal of Clinical Oncology, 2014, 32, 3021-3032. | 1.6 | 360 |
| 114 | Acute myeloid leukaemia (<scp>AML</scp>) with t(6;9)(p23;q34) is associated with poor outcome in childhood <scp>AML</scp> regardless of FLT3â€ITD status: a report from the Children's Oncology Group. British Journal of Haematology, 2014, 166, 254-259. | 2.5 | 58 |
| 115 | NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood, 2014, 124, 2400-2407. | 1.4 | 99 |
| 116 | Multimerin-1 (MMRN1) As Novel Adverse Prognostic Marker in Acute Myeloid Leukemia: A Report from the Childrenâ€™s Oncology Group. Blood, 2014, 124, 2330-2330. | 1.4 | 0 |
| 117 | Patient Factors Associated with Enrollment on an Acute Myeloid Leukemia Phase III Clinical Trial: A Report from the Childrenâ€™s Oncology Group. Blood, 2014, 124, 2286-2286. | 1.4 | 0 |
| 118 | Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3-ITD+ Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood, 2014, 124, 486-486. | 1.4 | 0 |
| 119 | Disease Characteristics and Prognostic Implications Of Cell Surface FLT3 Receptor (CD135) Expression In Pediatric Acute Myeloid Leukemia â€“ A Report From Childrenâ€™s Oncology Group. Blood, 2013, 122, 2609-2609. | 1.4 | 1 |
| 120 | Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Childrenâ€™s Oncology Group. Blood, 2013, 122, 491-491. | 1.4 | 40 |
| 121 | Impact Of Residual Disease On Survival In Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation For Acute Myeloid Leukemia In First Complete Remission. Blood, 2013, 122, 65-65. | 1.4 | 3 |
| 122 | Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Childrenâ€™s Oncology Group. Blood, 2013, 122, 931-931. | 1.4 | 1 |
| 123 | PIM3-SCO2 Fusion Is a Novel Transcription-Induced Chimera That Is Highly Prevalent In Childhood AML. Blood, 2013, 122, 2549-2549. | 1.4 | 3 |
| 124 | Genomic Architecture and Treatment Response In Pediatric Acute Myeloid Leukemia: A Report From The Childrenâ€™s Oncology Group. Blood, 2013, 122, 610-610. | 1.4 | 0 |
| 125 | Constitutional Telomerase-Associated Gene Variants In Pediatric Acute Myeloid Leukemia (AML) and In Association With Chemotherapy-Related Toxicities. Blood, 2013, 122, 1310-1310. | 1.4 | 0 |
| 126 | NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Childrenâ€™s Oncology Group and SWOG. Blood, 2013, 122, 488-488. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Duration Of Neutropenia Is Associated With Reduced Relapse Risk In Children With De Novo Acute Myeloid Leukemia: A Report From The Childrenâ€™s Oncology Group. Blood, 2013, 122, 2650-2650. | 1.4 | 0 |
| 128 | Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood, 2012, 120, 1581-1588. | 1.4 | 256 |
| 129 | AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia. Cancer, 2012, 118, 761-769. | 4.1 | 157 |
| 130 | Identification of Novel Somatic Mutations, Regions of Recurrent Loss of Heterozygosity (LOH) and Significant Clonal Evolution From Diagnosis to Relapse in Childhood AML Determined by Exome Capture Sequencing â€“ an NCI/COG Target AML Study. Blood, 2012, 120, 123-123. | 1.4 | 2 |
| 131 | WT1 snp rs16754 Genotype Predicts Treatment Related Mortality (TRM) in African-American and Asian Pediatric AML Patients: A Report From the Children's Oncology Group. Blood, 2012, 120, 1385-1385. | 1.4 | 1 |
| 132 | A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia: A Children's Oncology Group (COG) Study. Blood, 2012, 120, 3580-3580. | 1.4 | 4 |
| 133 | RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia. Blood, 2012, 120, 1278-1278. | 1.4 | 0 |
| 134 | Effectiveness of Supportive Care Measurements to Reduce Infections During Induction for Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Blood, 2012, 120, 1478-1478. | 1.4 | 0 |
| 135 | Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group.. Blood, 2012, 120, 2388-2388. | 1.4 | 0 |
| 136 | Expression of RUNX1 and RUNX1T1 Correlates with Cytogenetic Subgroups in Pediatric AML: A Report From the Children's Oncology Group. Blood, 2012, 120, 1425-1425. | 1.4 | 0 |
| 137 | Constitutional Telomerase-Associated Gene Variants Associated with Chemotherapy-Related Toxicities in Pediatric Acute Myeloid Leukemia (AML). Blood, 2012, 120, 1403-1403. | 1.4 | 0 |
| 138 | Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group. Blood, 2012, 120, 529-529. | 1.4 | 0 |
| 139 | Novel IRF8 Splice Variants Are Validated As a New Prognostic Biomarker for Adverse Outcome in an Independent Population of Pediatric Patients with AML.. Blood, 2012, 120, 2550-2550. | 1.4 | 0 |
| 140 | AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia. Blood, 2012, 120, 3604-3604. | 1.4 | 0 |
| 141 | Hematopoietic Cell Transplant Versus Chemotherapy As Consolidation Treatment for Pediatric AML with Poor-Risk Cytogenetics. Blood, 2012, 120, 127-127. | 1.4 | 0 |
| 142 | High EVI1 expression Is Associated with MLL rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group.. Blood, 2012, 120, 2530-2530. | 1.4 | 0 |
| 143 | Outcome of Pediatric Patients with Acute Myeloid Leukemia and -5/5q-Abnormalities Enrolled On Five Children's Oncology Group Acute Myeloid Leukemia Treatment Protocols. Blood, 2012, 120, 1414-1414. | 1.4 | 0 |
| 144 | Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Mulˆnster AML Study Group.. Blood, 2012, 120, 2516-2516. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Novel IL23R Splice Variant Is Associated with Worse Prognosis in Pediatric Patients with AML.. Blood, 2012, 120, 2546-2546. | 1.4 | 0 |
| 146 | Acute Myeloid Leukemia with t(6;9)(p23;q34) Is Associated Poor Outcome in Childhood AML Regardless of FLT3/ITD Status, A Report From Children's Oncology Group.. Blood, 2012, 120, 2541-2541. | 1.4 | 2 |
| 147 | Leukemic mutations in the methylationâ€associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2011, 57, 204-209. | 1.5 | 109 |
| 148 | Bias in estimating accuracy of a binary screening test with differential disease verification. Statistics in Medicine, 2011, 30, 1852-1864. | 1.6 | 11 |
| 149 | Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results,. Blood, 2011, 118, 3544-3544. | 1.4 | 1 |
| 150 | Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse â€“ a Report From the Children's Oncology Group,. Blood, 2011, 118, 3545-3545. | 1.4 | 1 |
| 151 | FACS Analysis of Stat3/5 Signaling Reveals Ligand Sensitivity As a Significant Prognostic Factor in Pediatric AML: A Children's Oncology Group Report. Blood, 2011, 118, 938-938. | 1.4 | 1 |
| 152 | Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status â€“ Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531. Blood, 2011, 118, 939-939. | 1.4 | 4 |
| 153 | Clinical Significance of CD33 Non-Synonymous Single Nucleotide Polymorphisms (SNPs) in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozogamicin-Containing Chemotherapy,. Blood, 2011, 118, 3489-3489. | 1.4 | 4 |
| 154 | The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group,. Blood, 2011, 118, 3555-3555. | 1.4 | 0 |
| 155 | Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. Blood, 2011, 118, 2617-2617. | 1.4 | 0 |
| 156 | TET2 Mutations Are Associated with Poor Outcome in Pediatric AML: A Report From the Children's Oncology Group. Blood, 2011, 118, 569-569. | 1.4 | 0 |
| 157 | The Prognostic Effect of High WT1 Gene Expression in Pediatric AML Depends on WT1 SNP rs16754 Status: A Report From the Children's Oncology Group (COG). Blood, 2011, 118, 1444-1444. | 1.4 | 0 |
| 158 | Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.. Blood, 2010, 116, 1071-1071. | 1.4 | 4 |
| 159 | Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group. Blood, 2010, 116, 1702-1702. | 1.4 | 1 |
| 160 | Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531. Blood, 2010, 116, 182-182. | 1.4 | 7 |
| 161 | Outcome of Adolescents and Young Adults (AYAs) with Non-M3 Acute Myeloid Leukemia (AML) Treated on Children's Oncology Group (COG) Trials Compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) Trials. Blood, 2010, 116, 183-183. | 1.4 | 4 |
| 162 | Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group. Blood, 2010, 116, 761-761. | 1.4 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | TET2 SNP rs2454206 (I1762V) Correlates with Improved Survival In Pediatric Acute Myelogenous Leukemia, a Report From the Children's Oncology Group. Blood, 2010, 116, 949-949. | 1.4 | 4 |
| 164 | Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421. Blood, 2010, 116, 954-954. | 1.4 | 2 |
| 165 | Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531. Blood, 2010, 116, 2740-2740. | 1.4 | 0 |
| 166 | The WT1 synonymous SNP rs16754 Is Associated with Higher mRNA Expression and Predicts Significantly Improved Outcome In Favorable-Risk Pediatric AML: a Report From the Children's Oncology Group. Blood, 2010, 116, 950-950. | 1.4 | 0 |
| 167 | Association of CD33 Expression Level with Disease Risk-Group Classification and Induction Response In Pediatric AML: A Report From the Children's Oncology Group. Blood, 2010, 116, 2732-2732. | 1.4 | 6 |
| 168 | Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study. Blood, 2010, 116, 762-762. | 1.4 | 2 |
| 169 | Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study. Blood, 2010, 116, 2737-2737. | 1.4 | 1 |
| 170 | High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group.. Blood, 2010, 116, 1072-1072. | 1.4 | 0 |
| 171 | Multiparameter FACS Analysis of G-CSF and IL-6 Signaling through Stat3 and Stat5 In Primary Pediatric AML Samples.. Blood, 2010, 116, 1051-1051. | 1.4 | 1 |
| 172 | High Expression of Neutrophil Elastase Predicts Improved Survival In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Blood, 2010, 116, 2762-2762. | 1.4 | 0 |
| 173 | The Prevalence of Fanconi Anemia Among Patients with De Novo Acute Myelogenous Leukemia. Blood, 2010, 116, 2232-2232. | 1.4 | 0 |
| 174 | Oxidant Pathway Functional Polymorphisms Influence the Risk of Myeloid Leukemia/Transient Myeloproliferative Disorder In Children with Down Syndrome.. Blood, 2010, 116, 1680-1680. | 1.4 | 0 |
| 175 | CBL Mutations In Pediatric Acute Myelogenous Leukemia Are a Rare Event, a Report From the Children's Oncology Group.. Blood, 2010, 116, 1659-1659. | 1.4 | 0 |
| 176 | A comparison of tests for restricted orderings in the threeâ€€class case. Statistics in Medicine, 2009, 28, 1144-1158. | 1.6 | 16 |
| 177 | Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood, 2009, 113, 6558-6566. | 1.4 | 166 |
| 178 | RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group.. Blood, 2009, 114, 2614-2614. | 1.4 | 2 |
| 179 | AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.. Blood, 2009, 114, 3076-3076. | 1.4 | 4 |
| 180 | Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia.. Blood, 2009, 114, 2610-2610. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.. Blood, 2009, 114, 1592-1592. | 1.4 | 0 |
| 182 | Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Blood, 2008, 111, 1044-1053. | 1.4 | 259 |
| 183 | Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants.. Blood, 2008, 112, 2255-2255. | 1.4 | 0 |
| 184 | Development and Evaluation of Classifiers. Methods in Molecular Biology, 2007, 404, 89-116. | 0.9 | 14 |
| 185 | Statistical Methods for Evaluating DNA Methylation as a Marker for Early Detection or Prognosis. Disease Markers, 2007, 23, 113-120. | 1.3 | 4 |
| 186 | Prevalence and Prognostic Implications of CEBPÎ± Mutations in Pediatric AML.. Blood, 2007, 110, 1441-1441. | 1.4 | 0 |
| 187 | Clinical implications of FLT3 mutations in pediatric AML. Blood, 2006, 108, 3654-3661. | 1.4 | 355 |
| 188 | Small sample estimation of relative accuracy for binary screening tests. Statistics in Medicine, 2004, 23, 21-34. | 1.6 | 7 |
| 189 | Estimating disease prevalence in two-phase studies. Biostatistics, 2003, 4, 313-326. | 1.5 | 53 |
| 190 | Impact of Granulocyte Colony-Stimulating Factor Use During Induction for Acute Myelogenous Leukemia in Children: A Report From the Children's Cancer Group. Journal of Pediatric Hematology/Oncology, 2002, 24, 627-635. | 0.6 | 29 |
| 191 | Distribution-free ROC analysis using binary regression techniques. Biostatistics, 2002, 3, 421-432. | 1.5 | 172 |
| 192 | Sample size calculations for comparative studies of medical tests for detecting presence of disease. Statistics in Medicine, 2002, 21, 835-852. | 1.6 | 80 |
| 193 | Assessing Accuracy of Oral Health Diagnostic Tests. , 0, , 205-218. | | 0 |
| 194 | IL-10 and TNFÎ± are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a childrenâ€™s oncology group report. Pediatric Hematology and Oncology, 0, , 1-12. | 0.8 | 3 |